{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:36:18Z","timestamp":1794274578814,"version":"4.9.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jns.2022.120268","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:15:21Z","timestamp":1650539721000},"page":"120268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["The humanistic burden of myasthenia gravis: A systematic literature review"],"prefix":"10.1016","volume":"437","author":[{"given":"Deborah","family":"Gelinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Parvin-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Jefferson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jns.2022.120268_bb0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3\u20134","key":"10.1016\/j.jns.2022.120268_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000487886","article-title":"Epidemiology of myasthenia gravis in Slovakia in the years 1977-2015","volume":"50","author":"Martinka","year":"2018","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jns.2022.120268_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116520","article-title":"Hospital admission and prevalence trends of adult myasthenia gravis in Finland in 2004\u20132014: A retrospective national registry study","volume":"407","author":"Sipila","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nrl.2014.09.007","article-title":"Prevalence of myasthenia gravis in the Catalan county of Osona","volume":"32","author":"Aragones","year":"2017","journal-title":"Neurologia"},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0025","doi-asserted-by":"crossref","first-page":"e00653","DOI":"10.1002\/brb3.653","article-title":"Diversity in mental fatigue and social profile of patients with myasthenia gravis in two different Northern European countries","volume":"7","author":"Sabre","year":"2017","journal-title":"Brain Behav"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0030","first-page":"355","article-title":"Myasthenia gravis: a population-based epidemiological study","volume":"109","author":"Rutledge","year":"2016","journal-title":"Ir. Med. J."},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0035","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.25068","article-title":"Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases","volume":"54","author":"Santos","year":"2016","journal-title":"Muscle Nerve"},{"issue":"11\u221212","key":"10.1016\/j.jns.2022.120268_bb0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00508-015-0796-5","article-title":"Estimation of incidence, prevalence, and age-at-diagnosis of myasthenia gravis among adults by hospital discharge records","volume":"127","author":"Foldvari","year":"2015","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000431036","article-title":"Geographical distribution of myasthenia gravis in Northern Europe - Results from a population-based study from two countries","volume":"44","author":"Boldingh","year":"2015","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jns.2022.120268_bb0050","author":"National Health Service"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jns.2022.120268_bb0060","author":"National Institute of Neurological Disorders and Stroke"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.jns.2022.120268_bb0070","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2022.120268_bb0080","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0090","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2022.120268_bb0095","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00415-019-09374-1","article-title":"Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis","volume":"266","author":"Alekseeva","year":"2019","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00415-009-5318-9","article-title":"Unsatisfactory outcomes in myasthenia gravis: influence by care providers","volume":"257","author":"Dunand","year":"2010","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13760-019-01209-0","article-title":"Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study","volume":"120","author":"Vitturi","year":"2020","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.jns.2022.120268_bb0115","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"issue":"11","key":"10.1016\/j.jns.2022.120268_bb0120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.jns.2022.120268_bb0125","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","article-title":"Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia)","volume":"33","author":"Basta","year":"2012","journal-title":"Neurol. Sci."},{"issue":"10","key":"10.1016\/j.jns.2022.120268_bb0130","doi-asserted-by":"crossref","first-page":"e00538","DOI":"10.1002\/brb3.538","article-title":"Fatigue in myasthenia gravis: risk factors and impact on quality of life","volume":"6","author":"Hoffmann","year":"2016","journal-title":"Brain Behav"},{"issue":"Supplement 1","key":"10.1016\/j.jns.2022.120268_bb0135","first-page":"506","article-title":"Anxiety and depression in myasthenia gravis patients","volume":"26","author":"Kalbus","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"21","key":"10.1016\/j.jns.2022.120268_bb0140","first-page":"21","article-title":"Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry","volume":"21","author":"Lee","year":"2018","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10072-008-0001-y","article-title":"Neuropsychological assessment in myasthenia gravis","volume":"30","author":"Sitek","year":"2009","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0150","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s13760-018-0915-y","article-title":"Quality of life in patients with MuSK positive myasthenia gravis","volume":"118","author":"Stankovic","year":"2018","journal-title":"Acta Neurol. Belg."},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/NRL.0000000000000238","article-title":"Quality of life of myasthenia gravis patients in regard to epidemiological and clinical characteristics of the disease","volume":"24","author":"Stojanov","year":"2019","journal-title":"Neurologist"},{"issue":"8","key":"10.1016\/j.jns.2022.120268_bb0160","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual. Life Res."},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0165","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mus.25540","article-title":"Cognitive fatigue in patients with myasthenia gravis","volume":"56","author":"Jordan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2022.120268_bb0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/ane.13017","article-title":"Lifestyle factors and disease-specific differences in subgroups of Swedish myasthenia gravis","volume":"138","author":"Westerberg","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2022.120268_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-13-132","article-title":"Fatigue in myasthenia gravis: Is it more than muscular weakness?","volume":"13","author":"Elsais","year":"2013","journal-title":"BMC Neurology"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0180","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.23296","article-title":"Myasthenia gravis: sleep quality, quality of life, and disease severity","volume":"46","author":"De Lapiscina","year":"2012","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.jns.2022.120268_bb0185","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mus.25386","article-title":"Assessment of physical fatigability and fatigue perception in myasthenia gravis","volume":"55","author":"Jordan","year":"2017","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0190","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mus.26069","article-title":"Fatigue is a relevant outcome in patients with myasthenia gravis","volume":"58","author":"Tran","year":"2018","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0195","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/occmed\/kqv087","article-title":"Beck depression inventory","volume":"66","author":"Jackson-Koku","year":"2016","journal-title":"Occup. Med. (Lond.)"},{"issue":"Suppl. 11","key":"10.1016\/j.jns.2022.120268_bb0200","first-page":"S467","article-title":"Measures of anxiety: state-trait anxiety inventory (STAI), Beck anxiety inventory (BAI), and hospital anxiety and depression scale-anxiety (HADS-A)","volume":"63","author":"Julian","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pbj.2017.02.002","article-title":"Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis","volume":"2","author":"Peres","year":"2017","journal-title":"Porto Biomedical Journal"},{"issue":"9","key":"10.1016\/j.jns.2022.120268_bb0210","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.clineuro.2010.06.018","article-title":"Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial","volume":"112","author":"Sieb","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"9","key":"10.1016\/j.jns.2022.120268_bb0215","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-010-5549-9","article-title":"Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy","volume":"257","author":"Winter","year":"2010","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0220","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/ene.13836","article-title":"EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis","volume":"26","author":"Barnett","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2022.120268_bb0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual. Life Outcomes"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/WNF.0b013e31823c5480","article-title":"Low-dose glucocorticoid therapy complements the pituitary-adrenocortical system and reduces anxiety and insomnia in myasthenia gravis patients","volume":"35","author":"Ito","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0235","first-page":"56","article-title":"Hope, coping, and quality of life in adults with myasthenia gravis","volume":"38","author":"Koopman","year":"2016","journal-title":"Canadian journal of neuroscience nursing"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0240","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"Journal of neuromuscular diseases"},{"issue":"24","key":"10.1016\/j.jns.2022.120268_bb0245","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3109\/09638280902893634","article-title":"Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravis","volume":"31","author":"Leonardi","year":"2009","journal-title":"Disabil. Rehabil."},{"issue":"6","key":"10.1016\/j.jns.2022.120268_bb0250","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.pjnns.2016.07.005","article-title":"Improvement of quality of life after therapeutic plasma exchange in patients with myasthenic crisis","volume":"50","author":"Rozmilowska","year":"2016","journal-title":"Neurologia i Neurochirurgia Polska"},{"issue":"129","key":"10.1016\/j.jns.2022.120268_bb0255","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"11","author":"Twork","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0260","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"The Lancet Neurology"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0265","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle and Nerve"},{"key":"10.1016\/j.jns.2022.120268_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2050312118819013","article-title":"Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study","volume":"6","author":"Bonanno","year":"2018","journal-title":"SAGE Open Medicine"},{"issue":"23","key":"10.1016\/j.jns.2022.120268_bb0275","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0280","first-page":"155","article-title":"Eculizumab in refractory generalized myasthenia gravis","volume":"21","author":"Manzano Garcia","year":"2019","journal-title":"Eur J Clin Pharm"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2022.120268_bb0290","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja","year":"2019","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"8","key":"10.1016\/j.jns.2022.120268_bb0295","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/2047-783X-14-8-364","article-title":"Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis - A long-term prospective open-label study","volume":"14","author":"Hanisch","year":"2009","journal-title":"European Journal of Medical Research"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0300","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00415-009-5279-z","article-title":"The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study","volume":"257","author":"Leonardi","year":"2010","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2022.120268_bb0305","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of Thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2022.120268_bb0310","series-title":"Neurology Conference: 71st Annual Meeting of the American Academy of Neurology","article-title":"Proof-of-concept and safety of the anti-FcRn antibody rozanolixizumab in patients with moderate-to-severe generalized myasthenia gravis (GMG): A phase 2a study","volume":"92","author":"Bril","year":"2019"},{"key":"10.1016\/j.jns.2022.120268_bb0315","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0320","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.jns.2022.120268_bb0325","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet neurol"},{"issue":"9","key":"10.1016\/j.jns.2022.120268_bb0330","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"16","key":"10.1016\/j.jns.2022.120268_bb0335","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2022.120268_bb0340","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"Kohler","year":"2011","journal-title":"J. Clin. Apher."},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0345","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s13311-015-0345-y","article-title":"A Double-Blinded, Randomized, Placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of Tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis","volume":"12","author":"Sanders","year":"2015","journal-title":"Neurother"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0350","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nmd.2016.11.009","article-title":"Ephedrine treatment for autoimmune myasthenia gravis","volume":"27","author":"Lipka","year":"2017","journal-title":"Neuromuscul. Disord."},{"issue":"23","key":"10.1016\/j.jns.2022.120268_bb0355","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120268_bb0360","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurology"},{"issue":"5\u20136","key":"10.1016\/j.jns.2022.120268_bb0365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000502818","article-title":"A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate\/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations","volume":"81","author":"Karelis","year":"2019","journal-title":"European Neurology"},{"issue":"08","key":"10.1016\/j.jns.2022.120268_bb0370","first-page":"08","article-title":"Cladribine in myasthenia gravis: a pilot open-label study","volume":"08","author":"Rejdak","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2022.120268_bb0375","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"04","author":"Neumann","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CND.0000000000000219","article-title":"Satisfactory response with achieving maintenance low-dose prednisone in generalized myasthenia gravis","volume":"20","author":"Abuzinadah","year":"2018","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"6","key":"10.1016\/j.jns.2022.120268_bb0385","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cortes-Vicente","year":"2018","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"11","key":"10.1016\/j.jns.2022.120268_bb0390","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","article-title":"Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial","volume":"89","author":"Beecher","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0395","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.jns.2022.120268_bb0400","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bjophthalmol-2014-306335","article-title":"Blepharoptosis surgery in patients with myasthenia gravis","volume":"99","author":"Litwin","year":"2015","journal-title":"Br. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.jns.2022.120268_bb0405","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.396","article-title":"Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients","volume":"5","author":"McGurgan","year":"2015","journal-title":"Brain Behav"},{"issue":"5","key":"10.1016\/j.jns.2022.120268_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126579","article-title":"Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study","volume":"10","author":"Konno","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0415","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mus.23626","article-title":"Safety of plasma exchange therapy in patients with myasthenia gravis","volume":"47","author":"Ebadi","year":"2013","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0420","first-page":"84","article-title":"Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases","volume":"3","author":"DeZern","year":"2013","journal-title":"American journal of Blood Research"},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0425","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0430","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2022.120268_bb0440","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2012.06825.x","article-title":"Further developments with antisense treatment for myasthenia gravis","volume":"1275","author":"Sussman","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jns.2022.120268_bb0445","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/ene.12703","article-title":"Myasthenia gravis: Descriptive analysis of life-threatening events in a recent nationwide registry","volume":"22","author":"Ramos-Fransi","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0450","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.surg.2008.11.009","article-title":"Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement","volume":"145","author":"Bachmann","year":"2009","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0455","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2022.120268_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.08.004","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study","volume":"407","author":"Murai","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"issue":"8","key":"10.1016\/j.jns.2022.120268_bb0465","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","article-title":"Fatigue in patients with myasthenia gravis. A systematic review of the literature","volume":"30","author":"Ruiter","year":"2020","journal-title":"Neuromuscul. Disord."},{"issue":"11","key":"10.1016\/j.jns.2022.120268_bb0470","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041249","article-title":"Quality of life in adults with multiple sclerosis: a systematic review","volume":"10","author":"Gil-Gonz\u00e1lez","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jns.2022.120268_bb0475","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1352458508099477","article-title":"The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated","volume":"15","author":"Marrie","year":"2009","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jns.2022.120268_bb0480","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.jns.2022.120268_bb0485","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"2","key":"10.1016\/j.jns.2022.120268_bb0490","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cen3.12188","article-title":"Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes","volume":"6","author":"Utsugisawa","year":"2015","journal-title":"Clinical and Experimental Neuroimmunology"},{"key":"10.1016\/j.jns.2022.120268_bb0495","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"16","author":"Lotan","year":"2020","journal-title":"J. Neurol."},{"issue":"15 Supplement","key":"10.1016\/j.jns.2022.120268_bb0500","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1212\/WNL.94.15_supplement.975","article-title":"Analysis of the Duke myasthenia gravis (MG) clinic registry: demographic and clinical characteristics (975)","volume":"94","author":"Sanders","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120268_bb0505","doi-asserted-by":"crossref","first-page":"116830","DOI":"10.1016\/j.jns.2020.116830","article-title":"Exploring outcomes and characteristics of myasthenia gravis: rationale, aims and design of registry \u2013 the EXPLORE-MG registry","volume":"414","author":"Anil","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.jns.2022.120268_bb0510","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.0000000000002405","article-title":"Myasthenia gravis exacerbation after discontinuing mycophenolate: a single-center cohort study","volume":"86","author":"Oskarsson","year":"2016","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22001307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22001307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:32Z","timestamp":1758383972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22001307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":102,"alternative-id":["S0022510X22001307"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120268","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The humanistic burden of myasthenia gravis: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120268"}}